CFTR and cystic fibrosis: Recently, in vitro studies have demonstrated that the CFTR modulator TRIKAFTA [consisting of the correctors elexacaftor (VX-445) and tezacaftor (VX-661) and the potentiator ivacaftor (VX-770)] improves CFTR cellular processing and trafficking, and it has been approved for patients with CF aged 6 yr and older who have at least one F508del mutation in the CFTR gene or other approved mutations.